Is urinary lipoarabinomannan the result of renal tuberculosis? : assessment of the renal histology in an autopsy cohort of Ugandan HIV-infected adults by Cox, Janneke A et al.
RESEARCH ARTICLE
Is Urinary Lipoarabinomannan the Result of
Renal Tuberculosis? Assessment of the Renal
Histology in an Autopsy Cohort of Ugandan
HIV-Infected Adults
Janneke A. Cox1,2*, Robert L. Lukande3, Sam Kalungi3,4, Eric Van Marck5, Koen Van de
Vijver6, Andrew Kambugu2, Ann M. Nelson7, Robert Colebunders1,8, Yukari C. Manabe2,9
1 Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium, 2 Infectious Diseases
Institute, Makerere University College of Health Sciences, Kampala, Uganda, 3 Department of Pathology,
College of Health Sciences, Makerere University, Kampala, Uganda, 4 Department of Pathology, Mulago
Hospital Complex, Kampala, Uganda, 5 Department of Pathology, University Hospital Antwerp, University of
Antwerp, Belgium, 6 Department of Diagnostic Oncology & Molecular Pathology, Netherlands Cancer
Institute—Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands, 7 Joint Pathology Center, Silver
Spring, United States of America, 8 Department of Epidemiology and Social Medicine, University of Antwerp,
Belgium, 9 Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of
Medicine, Baltimore, Maryland, United States of America
* jannekecox@xs4all.nl
Abstract
Objective
The detection of urinary lipoarabinomannan (LAM), a mycobacterial cell wall component, is
used to diagnose tuberculosis (TB). How LAM enters the urine is not known. To investigate
if urinary LAM-positivity is the result of renal TB infection we correlated the outcomes of uri-
nary LAM-antigen testing to renal histology in an autopsy cohort of hospitalized, Ugandan,
HIV-infected adults.
Methods
We performed a complete autopsy, including renal sampling, in HIV-infected adults that
died during hospitalization after written informed consent was obtained from the next of kin.
Urine was collected postmortem through post-mortem catheterisation or by bladder punc-
ture and tested for LAM with both a lateral flow assay (LFA) and an ELISA assay. Two pa-
thologists assessed the kidney histology. We correlated the LAM-assay results and the
histology findings.
Results
Of the 13/36 (36%) patients with a positive urinary LAM ELISA and/or LFA, 8/13 (62%) had
renal TB. The remaining 5 LAM-positive patients had disseminated TB without renal in-
volvement. Of the 23 LAM-negative patients, 3 had disseminated TB without renal involve-
ment. The remaining LAM-negative patients had no TB infection and died mostly of fungal
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and bacterial infections. LAM LFA had a sensitivity of 81% and specificity of 100% to diag-
nose TB at any location, and the LAM ELISA a sensitivity of 63% and a specificity of 100%.
54% (7/13) LAM LFA-positive patients were not on anti-TB treatment at the time of death.
Conclusion
Renal TB infection explained LAM-positivity in the majority of patients. Patients with dissem-
inated TB without renal involvement can also be diagnosed with LAM. This suggests that
other mechanisms that lead to urinary LAM-positivity exist in a minority of patients.
Introduction
In 2012, the estimated number of TB-HIV co-infected patients in sub-Saharan Africa (SSA)
was 825,000 and 320,000 co-infected patients died. Uganda has a high HIV and TB burden,
and in 2013 an estimated 48% of TB patients were co-infected with HIV [1–3].
Diagnosing TB in HIV co-infected patients is challenging [4]. Methods relying on mycobac-
terial detection all have important flaws. Sputum microscopy remains the most commonly
used method in SSA, however its sensitivity is low [5, 6]. Culture is the gold standard, but is not
widely available and has a relatively long turn-over time [7]. Mycobacterial DNA detection has
higher diagnostic sensitivity and provides results the same day, but in resource poor settings,
limited availability, technical requirements and costs are important disadvantages [8–10]. An-
other diagnostic approach is antigen detection: lipoarabinomannan (LAM), a lipopolysaccha-
ride component of the mycobacterial cell wall, can be detected in the urine of TB-infected
patients [11–15]. Overall, diagnostic sensitivity of the ELISA LAM assay in urine is poor. But
in HIV-infected patients with low CD4 cell counts (<50 cells/μL) sensitivity increases to 56–
85% [11, 12, 16–18]. Recently a point-of-care test for LAM in urine is developed, the Deter-
mine TB LAM lateral flow assay (LFA) (Alere, Waltham, MA, USA). This immunochromato-
graphic assay attaches colloidal gold-labelled antibodies to LAM that are captured by
immobilized LAM antibodies further along the test strip and form a visual band. LFA diagnos-
tic accuracy is comparable to the ELISA assay in HIV-TB co-infected individuals and increases
when CD4 cell counts decrease [18–20].
There is an incomplete understanding of how LAM enters the urine. A South African study
detected mycobacterial DNA in half of the LAM-positive urinary samples of HIV-infected pa-
tients, suggesting that LAM-antigenuria represents whole mycobacteria in the urine[21]. Afri-
can autopsy series found renal TB in 39–52% of TB-HIV co-infected adults not on
antiretroviral treatment [22–24]. Since extra-pulmonary and disseminated TB are more fre-
quent in severely immunosuppressed HIV-infected patients, renal TB could explain the higher
sensitivity of urinary LAM assays in this population.
We sought to investigate if urinary LAM-positivity is the result of renal TB infection. We
correlated the outcomes of urinary LAM-antigen testing to the histological findings in renal tis-
sue in an autopsy cohort of hospitalized, Ugandan, HIV-infected adults.
Methods
Ethics Statement
The study received ethical approval from the Joint Clinical Research Center Research and Eth-
ics Committee (Uganda), the Mulago Internal Review Board (Uganda) and the Institute of
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Tropical Medicine Institutional Review Board (Belgium). The study was registered by the
Uganda National Council of Science and Technology (HS1300).
Setting and population
This study is a sub-study of a larger autopsy study that was conducted from February—June
2013 in Mulago hospital, a tertiary-care hospital in Kampala. The methods used are described
in detail elsewhere[25]. In brief, HIV-infected adults (>18 years old) that died on one of the
medicine wards were included after written informed consent was obtained from their next of
kin. Post-partum deaths and deaths after trauma were excluded.
Autopsy and histological assessment
A complete autopsy took place within 4 hours after consent was obtained. Urine was collected
in a sterile container through post-mortem catheterisation or by puncturing the bladder during
the autopsy and was stored at -20°C directly after the procedure. The autopsy included routine
sampling of both kidneys (samples containing cortex, medulla and corticomedullary junction)
and additional sampling in case of any macroscopically abnormal lesion. Tissue was fixed in
10% formalin.
Hematotoxylin and eosin (H&E) slides were made for each tissue section and read by 2 ex-
perienced pathologists. In case of discrepancy, discussion between the two pathologists would
provide consensus. The general kidney histology was assessed on H&E stained slides. Addition-
al stains, including Ziehl-Neelsen (ZN), Periodic Acid-Schiff diastase and Jones silver staining
were done when requested by the pathologists. For the final (renal) diagnoses, the histological
findings were combined with the available clinical and macroscopic data.
TB was defined as the presence of acid-fast bacilli (AFB) in any organ or granuloma forma-
tion with presence of giant cells or (caseous) necrosis not otherwise explained. Renal TB was
defined as the presence of AFB in the kidneys or granuloma formation with presence of giant
cells or (caseous) necrosis not otherwise explained. HIV-associated nephropathy (HIVAN)
was defined as a constellation of glomerular, interstitial and tubular abnormalities or the pres-
ence of microcysts. If only tubular or interstitial disease was present, additional epithelial cell
hyperplasia or hypertrophy was required. Acute tubular necrosis (ATN) was defined as massive
coagulation necrosis of tubular epithelial cells and presence of granular casts.
The pathologists reading the slides were blinded to the outcome of the LAM-antigen
testing.
LAM testing
After all autopsies were performed, the urine samples were thawed to ambient temperature.
One millilitre of urine was heated to 95–100°C for 30 minutes and when cooled down, spun 15
minutes (10,000 rpm.). The supernatant was collected. LAM-antigen testing was done on an
unprepared defrosted sample, further referred to in the text as unprepared urine, and on the su-
pernatant. For the LFA testing, the Determine TB LAM was used and for ELISA testing, the
Clearview TB ELISA. Both tests were provided by Alere (Waltham, MA, USA).
For each collected urine sample, 60μL of unprepared urine and 60μL of supernatant was ap-
plied to a LFA test strip. After 25 minutes, 2 experienced lab technicians read the test strip by
comparing the LFA test result to the manufacturer-supplied reference card (grading from +1
to +5). The +1 cut-off point was used for positivity. In case of discrepancy between the two
readers, immediate discussion between them provided consensus.
For the ELISA assay, 0.1ml of supernatant was applied in duplicate on a 96-well plate. Test-
ing procedures were conducted according to manufacturer’s instructions, which included a
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duplicate positive and negative control on each plate. Immediately after processing, optical
density (OD) was measured at 450nm. The average OD for each sample was compared to the
cut-off for positivity/negativity. The cut-off was determined by adding 0.1 OD units to the av-
erage negative control OD value, as instructed by the manufacturer.
The lab technicians were blinded to the autopsy results.
Statistical methods
Data was analyzed using STATA version 11.0 (Stata Corp., Texas, USA). Proportions are re-
ported with 95% confidence intervals (CI) and non-normal distributed continuous variables as
a median with interquartile ranges (IQR). When comparing proportions, a Chi square or Fish-
er’s exact test was performed and when comparing non-parametric numerical variables, a
Mann-Whitney test. A p-value <0.05 was considered statistically significant.
Results
Patient characteristics
We collected urine from 38 autopsy-cases. One patient was excluded from further analysis be-
cause only one kidney block was retrieved after tissue processing. Another patient was excluded
because no differentiation could be made between disseminated (treated) Cryptococcus neofor-
mans infection and TB. This patient died 10 days after completing a 2-week course of ampho-
tericin-B and fluconazole for culture positive cryptococcal meningitis and had macroscopically
nodular growths in multiple organs and microscopically necrotic granulomas in the lungs, the
spleen and lymph nodes but additional staining with Grocott silver and ZN did not reveal any
causative microorganism.
The median age was 38 years (IQR 32–43), the median CD4 count 39 cells/μL (IQR 13–64).
Twenty patients (56%) were reported to be on antiretroviral therapy (ART) for a median dura-
tion of 21 days (IQR 14–183). Eight cases (22%) were reported to be on anti-TB treatment for a
median duration of 14 days (IQR 5–42). Characteristics were similar in TB-infected LAM-posi-
tive, TB-infected LAM-negative and TB-uninfected patients, although a trend of higher CD4
cell counts in TB-infected LAM-negative patients was observed when compared to TB-infected
LAM-positive patients (p = 0.07) (Table 1). Only 46% of the LAM-positive patients were on
TB-treatment.
Table 1. Patient characteristics.
Total (n = 36) TB-infected (n = 16) TB-uninfected* (n = 20)
LAM-positive (n = 13) LAM-negative (n = 3)
Gender (% female) 42 31 33 50
Median age (yrs; IQR) 38 (32–43) 39 (30–47) 38 (range 33–39) 37 (33–42)
Median CD4 count (cells/μL; IQR) 39 (13–64) 19 (11–39)** 63 (range 47–101)** 41 (17–205)
On ART (%) 56 62 0 60
Median duration of ART (days; IQR) 21 (14–183) 21 (14–21) - 148 (14–1095)
On anti-TB treatment (%) 22 46 0 10
Median duration anti-TB treatment (days; IQR) 14 (5–42) 8 (5–42) - 52 (14–90)
Median duration admission (days; IQR) 6 (2–11) 6 (2–9) 11 (range 3–11) 5 (2–11)
n: absolute number; yrs: years; IQR: inter-quartile range; ART: anti retroviral therapy; TB: tuberculosis
* including one patient with granulomatous infection not speciﬁed
**p = 0.07.
doi:10.1371/journal.pone.0123323.t001
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Urinary LAM and kidney histology
Thirteen patients had a positive LAM ELISA and/or LFA. Of these, 8 (62%) had histological ab-
normalities compatible with renal TB: 6 with AFB and 2 without AFB on ZN staining of the
renal tissue (Table 2 and Fig 1). The remaining 5 LAM-positive patients had disseminated TB,
but no histological abnormalities suggestive of renal TB: one had macroscopic white nodules
on one kidney but no microscopic lesions suggesting an infection and one had lymphocytic in-
filtrates on renal histology, a non-specific finding, and additional ZN staining was negative for
AFB.
The general kidney histology of the LAM-positive patients with renal TB showed normal
histology in 3/8, protein casts without tubulo- or glomerulopathy in 3/8 and atherosclerosis in
2/8. The kidney histology of the LAM-positive patients without renal TB showed minor-severe
glomerulopathy as part of HIVAN in 2/5, ATN and atherosclerosis in 1/5, protein casts with-
out tubulo- or glomerulopathy in 1/5 and protein casts with dilated tubules in 1/5 (Table 3).
Twenty-three patients (64%) had negative results in both LAM assays. Of these, 3 patients
had disseminated TB without histological abnormalities compatible with renal TB. None of
these 3 patients was on anti-TB treatment. Their general kidney histology showed moderate-se-
vere glomerulopathy as part of HIVAN, chronic pyelonephritis and atherosclerosis (n = 1),
ATN (n = 1), and no abnormalities (n = 1) (Tables 2 and 3).
The remaining 20 LAM-negative patients had no TB infection. The cause of death in these
patients included disseminated fungal infections (Cryptococcus neoformans, Aspergillus and
Candida), bacterial infections and malignancies (Kaposi’s sarcoma).
LAM lateral flow assay and LAM ELISA outcomes
In 10 patients, both LAM-assays were positive (Table 2). In these 10, LFA intensities ranged
from +4 to +5 and ELISA optical densities ranged from 0.777–3.645 (cut-off point for positivity
OD 0.291). Another 3 patients had a positive LFA and a negative ELISA. Of these, LFA intensi-
ties ranged from +1 to +4 and ELISA OD from 0.136–0.201. No difference was found in LFA
outcome between the unprepared and the supernatant urine samples; a 1-grade decrease of in-
tensity was noted in 2 cases and a 1-grade increase in 2 cases. For the ELISA and LFA negative
cases the ELISA OD ranged from 0.134–0.221.
Urinary LAM results in TB-infected patients
Of the 36 patients, 16 (44%) died of disseminated TB, all but 2 with AFB on ZN staining
(Table 2). LAM LFA had a sensitivity of 81% (13/16) and specificity of 100% (20/20) to diag-
nose TB at any location, and the LAM ELISA a sensitivity of 63% (10/16) and a specificity of
100% (20/20). Fifty-four percent of the LAM-positive patients were not receiving TB-
treatment.
Discussion
The majority of patients with positive urinary LAM results had histological evidence of renal
TB infection. In these patients, urinary LAM-positivity is probably the result of renal TB infec-
tion and reflects the presence of whole mycobacteria.
However, 5 LAM-positive cases (38%) had disseminated TB without evidence of renal TB
lesions. In theory, renal TB infection could have been present in these patient but remained un-
diagnosed because of sampling error (due to inadequate sampling of the lesion, loss of tissue
during processing and/or too superficial cutting of the tissue) or atypical histological
LAM & Renal Histology in HIV-TB Patients
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Table 2. Characteristics, laboratory outcomes and histological findings per case.
CHARACTERISTICS LAB TESTING HISTOLOGY
LFA/ intensity ELISA** KIDNEY AUTOPSY
DIAGNOSIS
Age
Sex
CD4 On ART/
duration*
On TB-tx/
duration*
Unpre-
pared
Super-
natant
TB-speciﬁc
abnormalities
Other abnormalities
ELISA POSITIVE AND LFA POSITIVE
47 M - No No P / 5 P / 5 P/1.911 Large
granuloma, AFB
+
Moderate-severe
atherosclerosis
Disseminated TB, AFB
+ kidney
30 M 12 Y / 21 No P / - - P/2.328 Large
granuloma, AFB
+
None Disseminated TB, AFB
+ liver and lymphnode
39 M - Y / 7 No P / 4 P / 4 P/0.777 Granuloma,
AFB+
None Disseminated TB, AFB
+ spleen
39 M - Y / - No P / 5 P / 4 P/2.723 Granuloma in
cortex, AFB+
Protein casts in tubuli, no
glomerulo- or tubulopathy
Disseminated TB, AFB
+ lung and brain
30 F - No No P / 5 P / 5 P/2.26 Multiple
granulomas,
AFB+
Protein casts in tubuli, no
glomerulo- or tubulopathy
Disseminated TB, AFB
+ kidney
40 M 24 Y / 21 Y / 42 P / 5 P / 5 P/1.707 Multiple
granulomas,
AFB-
Protein casts in tubuli, no
glomerulo- or tubulopathy
Disseminated TB, AFB
+ lung
48 M 64 No Y / - P / - P / 5 P/2.71 One small
granuloma,
AFB-
Moderate—severe
atherosclerosis
Disseminated TB AFB
+ lymph node
Intracerebral
hemorrhage
28 M - Y / 196 Y / 5 P / 5 P / 5 P/2.527 None Protein casts in tubuli, dilated
tubuli, no glomerulopathy
Disseminated TB, AFB
+ brain and spleen
Disseminated CN
infection
59 F 29 No Y / 2 P / 5 P / 5 P/3.645 None Aspeciﬁc lymphocytic
inﬁltrates Moderate
atherosclerosis, ATN
Disseminated TB, AFB
+ lung
25 M 48 Y / - Y / 8 P / 4 P / 4 P/0.877 None HIVAN with severe
glomerulopathy
Disseminated TB, AFB-
LFA POSITIVE AND ELISA NEGATIVE
32 M 13 Y / 14 No P / 4 P / 3 N/0.136 Multiple
granulomas,
AFB+
None Disseminated TB, AFB
+ lung and liver
48 F 4 No No P / 1 P / 2 N/0.201 None Protein casts in tubuli, no
glomerulo- or tubulopathy
Disseminated TB, AFB
+ lymphnode
Disseminated CN
29 F 9 Y / 28 Y / 42 P / 1 P / 2 N/0.165 None HIVAN with minor
glomerulopathy and ATN
Severe steatohepatitis
with liver failure
Disseminated TB, AFB-
ELISA NEGATIVE AND LFA NEGATIVE
33 M 47 No No N N N/0.183 None HIVAN with moderate-severe
glomerulopathy, chronic
pyelonefritis and
atherosclerosis
Disseminated Kaposi’s
sarcoma Disseminated
TB, AFB+ lung
39 M 63 No No N N N/0.189 None None Disseminated TB AFB
+ meninges
38 F 101 No No N N N/0.218 None ATN with hydronephrosis Disseminated TB, AFB
+ spleen
31 M - No No N N N/0.175 None None Pneumocystis jerovecii
pneumonia
(Continued)
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presentation. However, attention was paid to adequate sampling and tissue processing. There-
fore, other mechanisms that led to LAM-antigenuria may have been involved in these patients
(Fig 2).
Table 2. (Continued)
CHARACTERISTICS LAB TESTING HISTOLOGY
LFA/ intensity ELISA** KIDNEY AUTOPSY
DIAGNOSIS
Age
Sex
CD4 On ART/
duration*
On TB-tx/
duration*
Unpre-
pared
Super-
natant
TB-speciﬁc
abnormalities
Other abnormalities
32 M 17 Y / 112 No N N N/0.178 None Some autolysis Bacterial meningitis and
pneumonia
Disseminated CN
24 F - No No N N N/0.154 None None Liver failure probably
alcoholic
Intraventricular
hemorrhage
39 F 42 Y - No N N N/0.175 None None Liver cirrhosis etiology
unknown
30 F 7 Y / 1095 Y / 90 N N N/0.157 None Multiple small cysts Liver failure etiology
unknown
35 M - Y - No N N N/0.202 None Atherosclerosis and old renal
infarction, dilated lymph
vessels
Disseminated Kaposi’s
sarcoma
62 M - Y /- No N N N/0.142 None Atherosclerosis and recent
renal infarction
Myocardial infarction
45 M 201 Y / - No N N N/0.207 None None Sarcoma
37 M - No No N N N/0.195 None CN Disseminated CN
39 F - Y / - No N N N/0.221 None CN Disseminated CN
26 F 160 No - N N N/0.184 None None Candida meningitis
38 M - Y / 183 No N N N/0.134 None None Disseminated Kaposi’s
sarcoma
24 F 205 No No N N N/0.172 None None Bacterial sepsis
35 F - Y / 3 Y / 14 N N N/0.186 None ATN Bilateral Aspergillus
pneumonia
39 F 341 Y / 14 No N N N/0.201 None None Massive steatohepatitis
35 F 2 No No N N N/0.173 None CN Disseminated Kaposi’s
sarcoma Disseminated
CN
63 M 39 No No N N N/0.162 None None Chronic meningitis of
unknown etiology
Bacterial pneumonia
37 F 638 Y / 2190 No N N N/0.196 None Atherosclerosis and multiple
recent infarctions, no
glomerulosclerosis
Aspiration pneumonia
61 M - Y / 2 No *** N N N/0.187 None Atherosclerosis, possibly
early HIVAN
Bacterial pneumonia
45 F - No No N N N/0.205 None Chronic pyelonephritis,
atherosclerosis
Bacterial pneumonia
* in days ** Average optical density, cut-off point for positivity was 0.291 *** recently completed 6 months anti-TB treatment; LFA: lateral ﬂow assay;
ELISA: enzyme-linked immunosorbent assay; ART: antiretroviral therapy; TB: tuberculosis; M: male; F: female;-: exact intensity unknown but 1; Y: yes;
P: positive; N: negative; AFB: acid fast bacilli, CN: Cryptococcus neoformans infection; HIVAN: HIV-related nephropathy; ATN: acute tubular necrosis.
doi:10.1371/journal.pone.0123323.t002
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Direct entry from the bloodstream into the urine ofMycobacterium tuberculosis (MTB)
seems unlikely, due to its size compared to the size of the filtration slits of an intact glomerular
basement membrane (GBM) (Fig 2, Mechanism 2)[26]. LAM is immunogenic and anti-LAM
Fig 1. Macro-andmicroscopic images of TB in the kidney. A. Nodules on outer surface of the right kidney and B. in the kidney parenchyma C.
Tuberculoma in the kidney parenchyma D. Ziehl-Neelsen stain of a granuloma in the renal parenchyma showing glomeruli and tubules (x5) E. Microscopic
zoom of indicated area with a glomerulus and multiple acid fast bacilli (x40) F. Microscopic zoom of indicated area with multiple acid fast bacilli (x100).
doi:10.1371/journal.pone.0123323.g001
Table 3. Renal histology in TB-infected patients according to LAM-assay outcome.
Renal TB Other renal abnormalities
LAM+n = 13 Yes n = 8 None n = 3
Protein casts in tubuli without glomerulo- or tubulopathy n = 3
Moderate-severe atherosclerosis n = 2
No n = 5 HIVAN with minor-severe glomerulopathy n = 2
Aspeciﬁc lymphocytic inﬁltrates, ATN, moderate atherosclerosis n = 1
Protein casts in tubuli, dilated tubuli, no glomerulopathy n = 1
Protein casts in tubuli without glomerulo- or tubulopathy n = 1
LAM-n = 3 No n = 3 HIVAN, chronic pyelonephritis, atherosclerosis n = 1
ATN n = 1
None n = 1
n: absolute number; +: positive;-: negative; HIVAN: HIV-associated nefropathy; ATN: acute
tubular necrosis.
doi:10.1371/journal.pone.0123323.t003
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antibodies were detected in both urinary LAM-positive and negative HIV-TB co-infected pa-
tients[27, 28]. LAM caught in immune-complexes would also be too large the pass an intact
GBM (Fig 2, Mechanism 3). Glomerulopathy leading to GBM leakage and proteinuria would
allow presence of large molecules in urine. However, we found glomerulopathy in only 2 of the
5 LAM-positive cases without renal TB and in 1 of the 3 LAM-negative TB-infected cases.
Moreover, studies that assessed proteinuria found a weak (odds ratio 1.63 (95%CI 1.06–2.52))
or no correlation with LAM-positivity[11, 19, 21, 29].
LAM unbound to immune-complexes can readily pass the GBM (Fig 2, Mechanism 4 and
5)[30]. Uncomplexed LAM could circulate as a result of decreased ability to mount an immu-
noglobulin response or as the result of a misbalance in LAM-quantity compared to immuno-
globulin. If impaired tubular resorption plays any additional role is unknown (Fig 2,
Mechanism 5). Lastly, urogenital TB infection beyond the kidney parenchyma could lead to
LAM-antigenuria, however isolated TB infection of the ureter and bladder without renal in-
volvement seems non-existent and isolated TB infection of the male genital tract has been de-
scribed only sporadically (Fig 2, Mechanism 6) [31, 32]. We routinely inspected ureter, urinary
bladder and prostate and sampled them in case of macroscopic abnormality. As no abnormali-
ties suggestive of TB were observed, this mechanism seems unlikely.
Mycobacterial load is an important predictor of LAM-antigenuria and provides additional
support that either renal TB and/or entry of uncomplexed LAM is the cause of LAM-antige-
nuria. In addition, anti-TB treatment negatively affects urinary LAM detection [12, 21, 33].
More than one mechanism may be involved in LAM antigenuria and different mechanisms
Fig 2. Mechanisms leading to lipoarabinomannan antigenuria. 1. Renal TB 2. Passage of wholeMycobacterium tuberculosis through the glomerular
basement membrane into the urine 3. Passage of LAM captured by immune-complexes through the glomerular basement membrane into the urine 4.
Passage of uncomplexed LAM through the glomerular basement membrane into the urine 5. Impaired tubular resorption of uncomplexed LAM 6. Genital tract
TB (Fig. based on [21]). MTB:Mycobacterium tuberculosis; GBM: glomerular basement membrane; LAM: lipoarabinomannan.
doi:10.1371/journal.pone.0123323.g002
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can co-exist within one patient. To further differentiate between the mechanisms, urine of
LAM-positive patients should be examined to see if whole mycobacteria, individual LAM poly-
saccharides or both are excreted. Also 24-hour urinary protein excretion should be measured.
One criticism of the LAM lateral flow assay has been the decreased specificity compared to
sputum and blood culture gold standards. In our study, the LAM LFA was 100% specific.
Cross-reactivity of the LAM test has been described with urogenital Candida sp. [11]. Also
dust, soil and feces increased optical density in LAM ELISA, leading to false positivity of the
assay [34]. The absence of false-positive results in our study might be the result of the methods
we used to obtain the urine (postmortem catheter or bladder puncture) leading to relatively un-
contaminated urine samples.
The LAM LFA had a sensitivity of 81% to diagnose TB compared to the histologic gold stan-
dard and was more sensitive than the ELISA test. This sensitivity is higher than reported in
clinical studies, probably because of our population of terminally ill, severely immune-sup-
pressed patients[18–20].
No difference was found in LFA outcome when using unprepared or supernatant urine.
Therefore, heating and spinning of the urine with the objective to separate antigen-antibody
complexes did not improve diagnostic accuracy of LFA in our samples.
Lastly, we noted that less than half of the LAM LFA positive patients in our study were on
anti-TB treatment. The clinical use of LAM LFA in these patients may have allowed for a time-
lier diagnosis and prompt treatment.
There are several limitations to our study. We used, as most other studies, defrosted urine
samples to allow batch testing. Whether this negatively influenced LAM test results is un-
known. Moreover, we were unable to perform culture and/or PCR on our urine samples. This
would have allowed us to confirm the presence of whole mycobacteria in the urine and to dif-
ferentiate between MTB and non-tuberculous mycobacteria (NTM). ELISA LAM positivity in
urine is described in cases ofMycobacterium bovis infection. For other NTM infections, sensi-
tivity was 5–1000 fold lower compared to MTB[35]. To assess renal histology, we used conven-
tional microscopy and no electron microscopy. Subtle glomerular abnormalities and minimal
change nephropathy could therefore been missed. Lastly, we relied on the inpatient ward charts
for clinical information. Often limited diagnostic testing was performed pre-mortem and renal
function, urinary analysis or 24-hour urine collections to assess proteinuria were not available.
In conclusion, the majority of urinary LAM-positive patients in our study had renal TB in-
fection. Other mechanisms may contribute to LAM-antigenuria, however renal histological as-
sessment did not reveal a prominent role for glomerular or tubular abnormalities. Moreover,
urinary LAM LFA was found to be very sensitive and highly specific in the diagnosis of dissem-
inated TB infection in hospitalized HIV-infected patients of whom 53% were not on anti-TB
treatment at the time of death.
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